UroGen Pharma Reports Second Quarter 2021 Financial Results and Recent Corporate Developments
The U.S. FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to Jelmyto for the treatment of LG-UTUC.
- The U.S. FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to Jelmyto for the treatment of LG-UTUC.
- You should not receive JELMYTO if you have a hole or tear (perforation) of your bladder or upper urinary tract.
- Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with JELMYTO.
- JELMYTO and UroGen are registered trademarks of UroGen Pharma, Ltd.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210804005328/en/